Cargando…

SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION

BACKGROUND: Brain metastases (BMs) occur in 20–40% of patients with METex14 skipping NSCLC. Tepotinib, a highly selective MET inhibitor, demonstrated an objective response rate (ORR) of 49.1% and median duration of response (mDOR) of 13.8 months, in METex14 skipping NSCLC patients in the Phase II VI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leighl, Natasha, Bestvina, Christine, Patel, Jyoti, Le, Xiuning, Veillon, Remi, Anderson, Ian, Demedts, Ingel, Garassino, Marina Chiara, Mazières, Julien, Morise, Masahiro, Smit, Egbert, Eggleton, S Peter, O’Brate, Aurora, Otto, Gordon, Bruns, Rolf, Schumacher, Karl Maria, Paik, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354189/ http://dx.doi.org/10.1093/noajnl/vdac078.085

Ejemplares similares

TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION
por: Bestvina, Christine M, et al.
Publicado: (2021)

Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial
por: Mazieres, Julien, et al.
Publicado: (2023)

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
por: Veillon, Remi, et al.
Publicado: (2022)

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
por: Le, Xiuning, et al.
Publicado: (2022)

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer
por: Drusbosky, Leylah M., et al.
Publicado: (2021)

The Current Landscape for METex14 Skipping Mutations in Non–Small Cell Lung Cancer
por: Desai, Alisha, et al.
Publicado: (2022)

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study
por: Sakai, Hiroshi, et al.
Publicado: (2021)

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
por: Tanaka, Hisashi, et al.
Publicado: (2021)

Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
por: Błaszkowska, M., et al.
Publicado: (2022)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma: Case Report
por: Ninomaru, Taira, et al.
Publicado: (2021)

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
por: Fujino, Toshio, et al.
Publicado: (2022)

Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations
por: Paik, Paul K., et al.
Publicado: (2022)

EURISOL-DS METEX: Operation Manual for the METEX1-Exeriment in IPUL
por: E. Platacis, A. Zik (IPUL),F.Groeschel, S. Dementjev (PSI)
Publicado: (27/1)

Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
por: Makimoto, Go, et al.
Publicado: (2022)

Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44
por: Sohn, Sung-Hwa, et al.
Publicado: (2022)

Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B
por: Le, Xiuning, et al.
Publicado: (2023)

First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression
por: Inno, Alessandro, et al.
Publicado: (2023)

Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report
por: Hashiguchi, Mizuha Haraguchi, et al.
Publicado: (2021)

Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non–Small Cell Lung Cancer Harboring Mesenchymal–Epithelial Transition Exon 14 Skipping
por: Yang, Mo, et al.
Publicado: (2023)

Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer
por: Hong, Lingzhi, et al.
Publicado: (2021)

Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation
por: Takamori, Shinkichi, et al.
Publicado: (2022)

Syst
por: Vialettes, H
Publicado: (1971)

CFD post analysis of METEX-tests
por: Laure Blumenfeld, Cyril Kharoua, Yacine Kadi, Karel Samec, Mats Lindroos (CERN)
Publicado: (30/0)

Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report
por: Tseng, Liang-Wei, et al.
Publicado: (2022)

A case of successful desensitization treatment with tepotinib after tepotinib-induced rash
por: Tamura, Tomoki, et al.
Publicado: (2023)

EURISOL-DS METEX: CERN SAFETY COMMISSION RECOMMENDATIONS
por: J.Gulley (CERN: SC/GS)
Publicado: (27/1)

Microtubule disruption targets HIF-1α mRNA to cytoplasmic P-bodies for translational repression
por: Carbonaro, Marisa, et al.
Publicado: (2011)

EURISOL-DS METEX1: LDV measurement to detect Cavitations
por: Lettry, Jacques, et al.
Publicado: (27/1)

EURISOL-DS METEX: Cooling and Temperature Control of the Mercury Loop
por: Stefan Joray
Publicado: (27/1)

The SysteMHC Atlas project
por: Shao, Wenguang, et al.
Publicado: (2018)

SYST-14 D2C7 CAR EFFECTIVELY AND SAFELY TREATS EGFRWT AND EGFRVIII-EXPRESSING TUMORS FOLLOWING INTRACRANIAL ADMINISTRATION
por: Wilkinson, Daniel, et al.
Publicado: (2023)

The LHCb RICH Syste: Detector Performance
por: Matteuzzi, C
Publicado: (2013)

Pseudo-acute kidney injury secondary to tepotinib
por: Wijtvliet, Veerle, et al.
Publicado: (2022)

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non–Small-Cell Lung Cancer Harboring MET Exon 14 Skipping
por: Le, Xiuning, et al.
Publicado: (2021)

Fmr1 exon 14 skipping in late embryonic development of the rat forebrain
por: Corrêa-Velloso, Juliana C., et al.
Publicado: (2022)

Feature set expansion for the SysteMA software
por: Kirchner, Davide
Publicado: (2014)

SYST-08 ROLE OF THE MICROBIOME IN BRAIN TUMORS
por: Omer, Mohammed
Publicado: (2023)

Clinical and pathological characteristics of 11 NSCLC patients with c-MET exon 14 skipping
por: Chen, Hualin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4uaicneabttp1q6ju0eif2dq7e